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The boundaries of embryonic stem cell (ESC) research have extended considerably in recent years in
several important ways. Alongside a deeper understanding of the pluripotent state, ESCs have been
successfully integrated into various fields, such as genomics, epigenetics, and disease modeling. Significant
progress in cell fate control has pushed directed differentiation and tissue engineering further than ever
before and promoted clinical trials. The geographical distribution of research activity has also expanded,
especially for human ESCs. This review outlines these developments and future challenges that remain.Introduction
The isolation of mouse embryonic stem cells (mESCs) from
mouse blastocysts three decades ago dramatically advanced
the field of mouse genetics, resulting in the groundbreaking
technology of gene targeting. The impact of the derivation of
human ESCs (hESCs; Thomson et al., 1998) almost two decades
later was just as dramatic, placing the study of pluripotent stem
cells at the forefront of biomedical research. Indeed, in recent
years as the ethical constraints associated with hESC research
have become a less prominent topic of debate, the scientific
boundaries of this field have expanded considerably. In this
Perspective, we cover several aspects of this ‘‘expansion’’ and
discuss the major issues that have occupied the field in recent
years.
In the past 5 years, ‘‘core research’’ on ESCs, i.e., re-
search into their self-renewal and differentiation capacities,
took advantage of state-of-the-art genome-wide technologies
to extend our understanding of the pluripotent state. This
increasing understanding has allowed the ESC field to reach
beyond the boundaries of the laboratory, toward the fulfillment
of its promise for regenerative medicine, with increasing
numbers of preclinical and, more recently, clinical trials per-
formed with ESC-derived cells. This maturation, in turn, facili-
tated the entry of new players into the ESC field. A growing
number of physicians, regulatory agencies, and industrial com-
panies are joining the academically driven journey of ESCs
toward the clinic. During the past few years, ESCs have also
gone beyond their traditional role as a tool for studying pluripo-
tency and have become a fundamental player in various
domains of molecular biology; more and more studies make
use of mESCs and hESCs for answering general questions in
genetics, epigenetics, and cell biology and for developing novel
technologies whose applications may go beyond pluripotent
cells. The boundaries of ESC research have also spread in the
literal geographic sense across political borders, with laborato-
ries from all over the world making significant contributions to
the field.
The Global Village: ESC Research Worldwide
Recent years have seen increasing interest in ESCs throughout
the world. In the past 5 years, laboratories from 50 different
countries published papers about ESCs, more than doubling
the total output of original research papers in the field, relative666 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.to the prior 5 years. This increase is even more impressive
when considering research on hESCs: between 2007 and
2011, laboratories from 41 countries published papers using
hESCs, compared to only 27 countries between 2002 and
2006 (Figure 1), more than tripling the number of papers on these
cells. This expansion can probably be attributed, at least in part,
to the establishment of clear guidelines for hESC research in
many countries.
Although the increase in the total number of publications and
in the number of countries involved is especially remarkable for
hESCs, there is a similar trend for nonhuman ESC research,
mostly on mESCs, which also expanded considerably over the
same time frame (Figure 1). Importantly, this growth cannot be
credited merely to the breakthrough of induced pluripotent
stem cells (iPSCs), as papers that involve iPSCs were not
included in this analysis.
The growing global interest in ESC research is also reflected
by the relative contribution coming from various parts of the
world. While the United States is still the most prolific country
in the field, the relative ‘‘share’’ of papers published by laborato-
ries from Europe and Asia has become much more significant
(Figure 1). For example, China has doubled its share in the total
publication count, in both human and nonhuman ESC-related
research. In summary, the increasing number of articles that
come out every year, the number of contributing countries, and
the relative contribution of these countries all suggest that ESC
research is on the rise.
Inside the Network: Understanding Pluripotency
When examining the pluripotency literature from the last few
years, one is overwhelmed by the quantity and quality of
genome-wide studies performed in attempts to deconstruct
the pluripotent state. It seems that no cutting-edge tech-
nology has gone unnoticed by the ESC field, which harnessed
these state-of-the-art tools to uncover the global state of plu-
ripotency (e.g., its genome, transcriptome, proteome, methyl-
ome, etc.), in what could be aptly described as ‘‘the ‘Omics’
era of ESC research’’ (Loh et al., 2011). The large-scale
genome-wide studies exposed complex and dynamic multi-
layered regulation involving transcriptional networks, chromatin
modifications, and posttranscriptional regulation (Ng and
Surani, 2011; Orkin and Hochedlinger, 2011; Young, 2011)
(Figure 2).
Figure 1. ESC Research Distribution throughout the World
World maps comparing the distribution of stem cell research throughout the world between two 5 year periods: 2002–2006 and 2007–2011. The numbers of
publications involving human and nonhuman ESCs were assessed separately and are thus presented in separate maps. Nonhuman ESCs are mostly, but not
exclusively, mouse ESCs. The maps are color-coded by the absolute number of articles published by laboratories from each country. The total number of
contributing countries during the examined years appears in the upper right side of each map. Articles dealing with iPSCs were removed from the analysis.
Quantification of articles was carried out using ‘‘ISI Web of Science’’ (http://apps.isiknowledge.com).
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The core transcriptional regulatory network of pluripotency was
investigated in a series of studies using various genome-wide
chromatin-IP based technologies (ChIP-on-chip, ChIP-PET,
ChiP-seq, and biochip). Whereas the first studies identified the
key players of the network and its general architecture (Boyer
et al., 2005; Loh et al., 2006), recent analyses refined our
understanding of this network, revealing a set of distinct-yet-
intimately-connected modules that cooperate and regulate
each other (Chen et al., 2008; Kim et al., 2008, 2010). These
studies divided the pluripotent network to its two main compart-
ments, the Oct4-centric and the Myc-centric modules; revealed
the interactions within and between each of these modules;
highlighted the importance of coregulation and autoregulation
for the proper function of the network; and integrated novel
signaling pathways into it. More recently, the core pluripotency
genes were also shown to control germ layer fate choice, ex-
tending the original role of the pluripotent network beyond the
maintenance of self-renewal (Thomson et al., 2011). Comparison
of the mouse and human pluripotent networks revealed, quite
surprisingly, that species-specific transposable elements have
considerably altered the transcriptional pluripotent circuitry, so
that in each species the same core factors bind a distinct set
of TF-binding sites and play distinct roles in pluripotency regula-
tion (Kunarso et al., 2010; Wang et al., 2012).
Noncoding RNAs
Another recently identified layer of pluripotency regulation is that
of noncoding RNAs: micro RNAs (miRNAs) and large intergenicnoncoding RNAs (lincRNAs). The importance of miRNAs in
ESCs was demonstrated in several studies. Like their unique
characteristic mRNA signature, ESCs exhibit a defined charac-
teristic miRNA signature (Marson et al., 2008). Global loss of
miRNAs resulted in defects in both self-renewal and differentia-
tion, whereas specific miRNAs were found to regulate ESC cell
cycle, expression of pluripotency factors, and differentiation
(Martinez and Gregory, 2010). The miRNAs themselves are,
in turn, regulated by pluripotency factors such as Lin28
(Viswanathan et al., 2008), demonstrating the crosstalk between
layers of pluripotency regulation. More recently, hundreds of
lincRNAs that are involved in the control of the pluripotent state
were also discovered (Guttman et al., 2009). Many of them were
reported to be bound by Oct4 and Nanog in their promoter
regions, directly integrating them into the core pluripotency
circuitry (Guttman et al., 2009). Specific lincRNAs were already
reported to be essential for pluripotency (Sheik Mohamed
et al., 2010), but much is left to be discovered regarding
their role.
Proteomics
Proteomic approaches have recently revealed interactions
between the core pluripotency proteins, contributing to the
growing understanding of pluripotency (Pardo et al., 2010;
Wang et al., 2006). Further studies added phosphorylation
dynamics as another layer of regulation in ESCs, identifying
significant changes in the phosphoproteome of ESCs during
their differentiation (Brill et al., 2009; Van Hoof et al., 2009). The
study of protein interactions also shed light on the importantCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 667
Figure 2. Major Achievements and
Challenges of ESC Research
A schematic representation of the main topics
in ESC research in recent years. The major ad-
vancements in each of these topics, and the
challenges that lie ahead, are elaborated in the
text.
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between core transcription factors and chromatin modifiers/
remodelers were shown to play a crucial part in maintaining
the ‘‘open’’ chromatin state, which is unique for pluripotent cells
(Gaspar-Maia et al., 2011). Moreover, there are direct regulatory
interactions between these transcription factors and chromatin
remodelers (Ang et al., 2011; Gaspar-Maia et al., 2009), further
stressing their importance for the pluripotent state.
Epigenetic Control
One of themost remarkable achievements in recent pluripotency
research is its intimate involvement in groundbreaking dis-
coveries in epigenetics, elucidating novel layers of regulation in
the complex control of the pluripotent state (Meissner, 2010).
At the level of DNA methylation, various studies characterized
ESC-specific methylation profiles and linked them directly to
the core transcriptional networks of ESCs (Fouse et al., 2008;
Meissner et al., 2008). A recent study applied Methyl-seq tech-
nology to map the ESC methylome at a single-base resolution,
revealing a novel class of DNA methylation at non-CpG sites
(Lister et al., 2009). These unique non-CpG methylations are
enriched in exons of highly expressed genes (Lister et al., 2009)
but appear to be dispensable for pluripotency (Ziller et al., 2011),
so their role in regulation of gene expression is still unclear. In
another major discovery, a novel type of DNA methylcytosine
modification was recently discovered in ESCs in which the
Tet-family proteins Tet1 and Tet2 transform methylated cyto-
sines into 50-hydroximethylcytosines (5hmC) (Ito et al., 2010;
Koh et al., 2011; Pastor et al., 2011; Tahiliani et al., 2009).
This series of studies demonstrated that Tet1 and Tet2 affect
self-renewal and differentiation of mESCs.
Another layer of epigenetic regulation that has been studied
extensively in ESCs is histone modifications. ESCs are charac-
terized by bivalent domains generated by the co-occupation
of the transcription start sites of genes that control cell fate deci-
sions by the activating mark H3K4me3 and the repressive mark
H3K27me3 (Bernstein et al., 2006). This phenomenon has drawn
much interest in the field, as the bivalent domains are considered668 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.to ‘‘poise’’ genes for their rapid activa-
tion upon differentiation. Recent studies
have improved our understanding of
the molecular mechanism that underlies
these unique domains, demonstrating
the important role of the polycomb
group (PcG) proteins PRC1 and PRC2
(Margueron and Reinberg, 2011), and
introducing new players that participate
in the generation and maintenance of
this delicate balance of modifications
(Margaritis and Holstege, 2008; Pasini
et al., 2010; Peng et al., 2009). Otherhistone modifications such as H3K9 methylation have also
been studied in ESCs (Wen et al., 2009), and together these
studies begin to decipher what seems to be an ESC-specific
‘‘histone code.’’
Having discovered elements that participate in regulating plu-
ripotency, the main challenge that lies ahead seems to be the
integration of all these ‘‘layers,’’ ‘‘modules’’ and ‘‘subnetworks’’
into a consolidated regulatory circuitry. Attempts to describe
the crosstalk between different layers of regulation have already
been reported, connecting, for example, gene expression with
DNA methylation (Bock et al., 2011), transcription with histone
modifications and protein levels (Lu et al., 2009), or DNA methyl-
ation with histone modification (Vire´ et al., 2006). With the
increasing focus on combinatorial regulation and on crosstalk
between network elements, we expect many more exciting
‘‘connections’’ to be revealed in the future.
One but Not the Same: Emerging Variability
of the Pluripotent State
The increasing understanding of the molecular mechanisms that
govern pluripotency inspired fruitful discussions regarding
the nature of the pluripotent state and helped refine the very
definition of the term ‘‘pluripotency.’’ The similar yet distinct
pluripotent states of various types of ESCs were coined ‘‘dif-
ferent flavors of pluripotency’’ (Buecker and Geijsen, 2010),
and as our understanding of these pluripotent states is becoming
more solid, so does our control of the transitions between them.
Developmental Identity of PSCs
The focus of investigation in this area is the difference between
mouse embryonic and epiblast stem cells (ESCs and EpiSCs,
respectively), and between mESCs and hESCs. MESCs are
derived from the inner cell mass of blastocysts, while mouse
EpiSCs are derived from postimplantation epiblasts (Brons
et al., 2007; Tesar et al., 2007); consequently, these cell types
differ in their morphology, culture requirements, developmental
potential, expression profile, and amenability to homologous
recombination. These differences led to the emergence of the
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tent cells (Nichols and Smith, 2009). Recent work showed that
mouse cells can acquire ‘‘metastable’’ pluripotent states that
could be interconverted by endogenous genetic determinants
or by exogenous factors (Hanna et al., 2009).
HESCs share many features with mESCs but, intriguingly,
they also share some of their characteristics with mouse
EpiSCs, suggesting that they may represent the primed ESC
state and therefore may not harbor the full developmental poten-
tial of naı¨ve ESCs. Recently, several groups reported the deriva-
tion of hESCs and hiPSCS with biological properties similar to
those of mESCs (Buecker et al., 2010; Hanna et al., 2010; Li
et al., 2009; Wang et al., 2011a). These hESCs exhibited
morphology, growth properties, expression profiles and
signaling dependence that were comparable to those of mESCs,
but they were not stable in the absence of genetic manipula-
tions. Whether these naı¨ve hESCs are indeed superior to
their primed counterparts in terms of developmental potential
remains to be determined; however, the fact that culture condi-
tions are sufficient to interconvert between pluripotent states,
both in mESCs and in hESCs, indicates that plasticity in the
pluripotent state is more widespread than was previously
appreciated.
Heterogeneity of PSCs
The variability between ESCs has received attention from
other directions as well; in recent years, ESCs were shown
to be more heterogeneous than previously thought. Both
intraculture and interculture heterogeneity exist: within undiffer-
entiated cultures of mESCs and hESCs and of mouse
EpiSCs, distinct subpopulations were identified, differing in their
expression of molecular markers and in their differentiation
potential and therefore presumed to correspond to distinct
developmental stages (Canham et al., 2010; Han et al., 2010;
MartinezArias andBrickman, 2011; Stewart et al., 2010; Toyooka
et al., 2008). Between undifferentiated hESC lines, large-scale
comparisons revealed differences in gene expression and in
differentiation, suggesting that not all ESCs lines are equally
suitable for any given purpose (Adewumi et al., 2007; Bock
et al., 2011).
ESC to Every Lab: Advances in ESC Derivation
and Propagation
The techniques for deriving, propagating, and banking ESCs
have significantly improved in recent years, and these types of
advances are key for moving ESCs toward the clinic (Figure 2).
Much progress has been made in adapting culture conditions
to enable rapid and efficient thawing, passaging, and cryopres-
ervation of hESCs. Themost notable discovery in this regard was
probably that the Rho-associated kinase (ROCK)-inhibitor
Y-27632 permits the survival of dissociated hESCs (Watanabe
et al., 2007). Follow-up studies uncovered the molecular mech-
anism that underlies the high sensitivity of hESCs to dissociation
(Chen et al., 2010; Ohgushi et al., 2010) and also utilized this
inhibitor for deriving and propagating hESCs in suspension
(Amit et al., 2010; Steiner et al., 2010).
Several groups have also directed much effort at determining
the components of defined media that would enable feeder-
free growth of hESCs (Akopian et al., 2010) and eliminating
animal products from such media, thus making it xeno-free(Lei et al., 2007; Valamehr et al., 2011). These efforts culminated
in the generation of good manufacturing practice (GMP)
clinical-grade hESCs (Unger et al., 2008). In order to standardize
the use of hESCs in biomedical research and, eventually, in
the clinic, consensus guidelines for banking and supply of
hESCswere proposed (International StemCell Banking Initiative,
2009).
As human ESC lines are now derived on a weekly basis,
the ethnical diversity within the human ESC pool has greatly
expanded so that it currently represents dozens of different
ethnic backgrounds (Amps et al., 2011). This diversity will be
important for the study of ethnically relevant diseases, for
the removal of confounding effects due to specific genetic
backgrounds, and for the banking of hESCs that would be
compatible with as large a population as possible.
Apart from the abovementioned advances in the culture of
hESCs, derivation and culture techniques were also developed
in recent years for ESCs of various species, expanding the
repertoire of pluripotent stem cells available for research. In
addition tomouse,monkey, and human ESCs, in the past 5 years
ESC lines were derived from multiple species including rabbit,
canine, and—most importantly—rat (Martins-Taylor and Xu,
2010). These stem cell types should enhance our understanding
of the pluripotent state and, especially in the case of the rat,
enable the generation of novel model animals for studying
human disease.
Eyes on the Target: ESCs in Regenerative Medicine
Many clinical conditions such as neurodegenerative disorders,
diabetes, and some forms of heart and hepatic failure are caused
by loss of functionality or insufficient quantity of a particular cell
type. The potential of hESCs to differentiate into any cell type of
the human body raised the hope for treatment of these clinical
conditions and has thus drawn hESCs into the public spotlight.
Indeed, exciting recent progress is paving the hESC path into
the practice of regenerative medicine (Figure 2).
Directing Differentiation
For hESCs to live up to expectations, it will be essential to control
their differentiation course. One of the most efficient strategies
designed to control a pluripotent cell fate is the recapitulation
of developmental steps through which cells assume a specific
fate during normal development (Murry and Keller, 2008). The
first step in the differentiation of a pluripotent stem cell is
transition into one of the three embryonic germ layers: the ecto-
derm, mesoderm, and endoderm. Multiple studies that applied
knowledge of developmental biology to ESC differentiation dem-
onstrated that despite the known differences between hESCs
and mESCs (Nichols and Smith, 2009), the signaling pathways
that control primary differentiation are very similar (Cohen and
Melton, 2011; Murry and Keller, 2008).
After acquiring their initial lineage identity, application of
various growth factors and culture conditions can continue to
direct the cells along multiple differentiation paths. Recently,
small molecules have become more useful in differentiation
protocols, presenting an appealing alternative to recombinant
growth factors, especially when considering the potential for
mass production of cells for clinical use (Rubin, 2008). Small
molecules are less expensive and more stable than recombinant
proteins and can contribute to the development of fully definedCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 669
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differences between batches of reagents, which can
reduce experimental variance and help establish reproducible
differentiation protocols. However, in some cases there are
no known chemical compounds that modulate the desired
signaling pathway. In such cases, unbiased screening offered
a potential solution. In a landmark study, thousands of
chemical compounds were screened in order to identify
molecules that can replace Activin A in the induction of defini-
tive endoderm (DE) (Borowiak et al., 2009). Two such small mole-
cules were uncovered in both mESCs and hESCs. Additional
studies used the unbiased screening approach to efficiently
produce desired ESC derivatives such as pancreatic progenitor
cells and cardiomyocytes (Chen et al., 2009; Takahashi et al.,
2003).
Advances in the genetic manipulation of ESCs (Giudice and
Trounson, 2008) have enabled the successful generation of
several fluorescent reporter hESC lines that are extremely
useful for a variety of applications. They can be used to
distinguish undifferentiated hESCs from their differentiated
derivatives (Eiges et al., 2001) or to visualize the appearance of
desired differentiated cells in culture (Lavon et al., 2004; Singh
Roy et al., 2005). Moreover, reporter cell lines enable the isola-
tion and analysis of various cell populations using fluores-
cence-activated cell sorting (FACS) even without previous
knowledge of specific cell surface markers or available anti-
bodies. The reporter cell lines are also valuable for micros-
copy-based high-throughput screening and can therefore assist
with the optimization of differentiation protocols. The engraft-
ment, survival and integration of transplanted cells can be
tracked more easily using such reporter hESCs. Although they
are mostly useful for in vitro analyses and preclinical studies,
reporter cell lines may be beneficial for determining the fate
and function of transplanted cells in clinical trials as well (Ellis
et al., 2010).
The tremendous progress in applying understanding of em-
bryognesis to differentiation protocols has enabled the genera-
tion of diverse cell types in vitro, including highly specified cells
such as retinal pigment epithelium (RPE) (Idelson et al., 2009),
mechanosensitive hair cells (Oshima et al., 2010), and primordial
germ cells (Hayashi et al., 2011). However, there are still many
challenges on the way to the ultimate goal of ‘‘cells on demand.’’
Differentiation is a stepwise process, passing through several
intermediate progenitor cells on the way to a fully-differentiated
cell of interest. The first differentiation step into the desired
germ layer is usually the most efficient step, and the dif-
ferentiation efficiency often decreases with each step of the
protocol (Cohen and Melton, 2011). As a result, the end product
is usually a heterogeneous cell population that contains only low
percentage of the specific cell type. A major challenge will there-
fore be to improve the differentiation efficacy and design reliable
methods for isolating the desired cell populations. An appealing
alternative can be to propagate intermediate progenitor cells, as
was recently demonstrated with definitive endoderm progenitor
cells (Cheng et al., 2012). Another related challenge is the re-
producibility of differentiation protocols. Different batches of
reagents and slight differences in cell culture techniques some-
time make it very difficult to recapitulate differentiation protocols
successfully and with comparable efficiency rates to those orig-670 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.inally reported. The distinct differentiation propensity of different
hESC lines (Bock et al., 2011) adds to this complexity, because
it compromises the generalization of some differentiation proto-
cols. Of note, most ESC-derived differentiated cells are not fully
mature, and their in vitro maturation is another obstacle that
awaits a solution (though, in some cases, maturation does take
place in vivo after cell transplantation (Hayashi et al., 2011; Kriks
et al., 2011; Kroon et al., 2008)).
Generation of Complex Differentiated Cell Types
The main focus of most directed differentiation experiments is
to maximize the derivation of one desired cell type for cell
replacement therapy. The replacement of complex tissues,
however, presents a greater challenge that involves differentia-
tion into several cell types with a three-dimensional (3D) organi-
zation. Recently, two different approaches have made progress
toward meeting this challenge. The first approach makes use
of the potential of ESCs to respond to extrinsic signals and
recapitulate developmental cell fate decisions to generate
‘‘tissues in a dish.’’ Several recent studies demonstrated that
ESCs can not only differentiate to all cell types, but also generate
organizer cells that may affect the fate of adjacent cells during
embryogenesis (Sharon et al., 2011). Moreover, the cells
possess in vitro self-organization capacity and can therefore
generate organized and complex 3D tissues, such as cortical
structures (Eiraku et al., 2008), the optic cup (Eiraku et al.,
2011), adenohypophysis (Suga et al., 2011), and intestinal tissue
(Spence et al., 2011). The second approach is the in vivo gener-
ation of tissues and organs using chimeric animals. In a remark-
able experiment, xenogeneic organ complementation was
achieved when rat pluripotent stem cells were injected into
mouse blastocysts that lacked the Pdx1 gene. As a result, the
rat-mouse chimera’s pancreas was composed exclusively of
rat cells, demonstrating the feasibility of organ generation
through interspecies chimeras (Kobayashi et al., 2010). As the
generation of viable chimeras from a nonhuman primate was
recently demonstrated (Tachibana et al., 2012), these break-
throughs raise fascinating possibilities regarding organ gen-
eration but also raise significant technical, legal, and ethical
questions.
Preclinical Evaluation
Before transplantation of differentiated cells into patients, it is
essential to conduct pre-clinical trials to demonstrate the inte-
gration capacity and functionality of the cells in animal models.
Finding an appropriate animal model and analyzing the mecha-
nism that underlies the observed improvements can be a chal-
lenging task. Demonstrating the functionality of differentiated
cells in an animal model that entirely lacks the relevant cell
type is the most stringent and straightforward approach; for
example, several groups demonstrated the potential of hESC-
derived b cells (Kroon et al., 2008) and RPE cells (Idelson et al.,
2009) to functionally replace their in vivo equivalents. Impor-
tantly, most in vivo transplantation experiments are currently
conducted in murine models, and the scalability of these assays
thus remains an open question. Tackling this issue, a recent
study demonstrated the in vivo survival, integration, and function
of hESC-derived dopaminergic neurons in rat and mouse
Parkinson’s disease models and went on to show their survival
and integration in parkinsonian adult rhesus monkeys (Kriks
et al., 2011).
Cell Stem Cell
PerspectiveClinical Studies
The progress in various aspects of ESC technology, discussed
above, has established a solid platform for therapeutic imple-
mentation. Although some safety issues as well as differentiation
and pre-clinical challenges are still unresolved, it seems as
though hESCs are starting to fulfill their promise, as reflected
by a couple of ongoing clinical trials. In these pioneering clinical
trials, differentiated derivatives of hESCs were transplanted
into patients suffering from various clinical conditions: spinal
cord injury, dry age-related macular degeneration (AMD), and
Stargardt’s disease (Goldring et al., 2011; Trounson et al.,
2011). This encouraging progress was hindered by the surprising
decision of Geron, the first company that took ESCs to the clinic,
to terminate all ESC-related experiments and ongoing clinical
trials. This blow, however, was somewhat balanced by the
positive preliminary report of Advanced Cell Technology (ACT),
describing the results of their first hESC-based clinical trial in
human patients (Schwartz et al., 2012). In this report, hESC-
derived RPE cells were transplanted into patients with either
AMD or Stargardt’s disease. Four months after the implantation,
the survival and engraftment of the cells, together with functional
visual improvement, were identified, whereas no signs of tumor-
igenicity or immune rejection were observed (Schwartz et al.,
2012). These preliminary clinical results, together with the
ever-improving differentiation protocols into highly specified,
complex and mature cell types, suggest that a new era of
hESC-based therapy might not be very far away.
Better Safe Than Sorry: The Tumorigenicity
and Immunogenicity of ESCs
As human ESC products get closer to the bedside, safety
issues have become a serious hurdle that must be overcome
before ESC-derived cells can be routinely injected into patients
(Goldring et al., 2011). The major safety problem the field is
currently facing is the potential tumorigenicity of the cells, mainly
due to residual undifferentiated cells. Several approaches
to selectively remove undifferentiated cells from culture have
been suggested in order to solve this problem, including the
use of genetic labeling, ablation of teratoma-specific genes,
sorting out pluripotent stem cells based on antibodies against
pluripotent-specific molecules, and specific cytotoxic anti-
bodies (Ben-David and Benvenisty, 2011). Most recently, bio-
markers unique to human pluripotent stem cells were used to
eliminate pluripotent stem cells from mixed populations (Tang
et al., 2011; Wang et al., 2011b). Concomitantly, efforts are being
made to characterize the most likely tumors, i.e., teratomas and
teratocarcinomas, in an attempt to prevent their formation (Blum
et al., 2009; for a discussion of the appropriate terminology for
these tumors, see Damjanov and Andrews, 2007; Lensch and
Ince, 2007). Although no tumor formation was reported in the
preliminary report of the first clinical trial with ESC-derived cells
(Schwartz et al., 2012), the tumorigenicity risk has not been
resolved yet and remains a concern that limits the number of
cells injected into human patients.
Another concern that may affect the safety of ESC-based
treatments is their genomic stability in culture. In recent years,
large-scale comparison studies revealed recurrent genomic
aberrations in hESCs and began to pinpoint the genes that drive
these frequent aberrations (Amps et al., 2011; Baker et al., 2007;Mayshar et al., 2010). Some of these aberrations may be associ-
atedwith oncogenic transformation, and thuswould increase the
tumorigenicity of the cells (Baker et al., 2007; Ben-David et al.,
2011; Lefort et al., 2008). Until strategies to prevent the accumu-
lation of such genomic alterations in ESC cultures are devel-
oped, the genomic integrity of the cells needs to be monitored
carefully prior to their clinical application. It is worth noting that
the genomic instability of ESCs is deleterious for additional
reasons: it may compromise their differentiation propensity,
the functionality of the differentiated cells, and their usefulness
for disease modeling and drug screening.
The immunogenicity of ESCsandof ESC-derived cells is a third
issue related to the safety—and, obviously, to the success—of
ESC-based treatments (Kadereit and Trounson, 2011). HLA
matching is a major hurdle for hESC-based therapies, especially
for treatments of tissues that are not immune privileged. Recent
preclinical and clinical trials applied pharmacological immuno-
suppression to avoid graft rejection (Kriks et al., 2011; Schwartz
et al., 2012); however, in one case the immunosuppression was
shown to be incomplete (Kriks et al., 2011) and in another the
patient did not comply with the immunosuppression regimen
(Schwartz et al., 2012), indicating that this important issue is
not fully resolved. Although some strategies for tolerance induc-
tion have been suggested (Robertson et al., 2007), the main
strategy for circumventing this obstacle remains the assembly
of ESCs with diverse major histocompatability complex (MHC)
haplotypes in the ESC banks that are founded these days
throughout the world.
ESCaping Drug Attrition: ESCs in the Service
of Toxicology
Assuring the safe use of new drugs requires the analysis of their
safety in the developing embryo and in the adult. In recent years,
hESCs have begun to play a major role in toxicology assays
(Laustriat et al., 2010). The pluripotent capacity of the cells and
their ability to differentiate into many cell types make them
a valuable pharmacological tool in three main ways (Figure 2).
First, hESCs can be used for screening of teratogens, com-
pounds that are selectively detrimental for the embryo or the
fetus, based on the ability of hESCs to mimic early stages of
human development (Mayshar et al., 2011; West et al., 2010).
The second aspect is drug metabolism, which primarily takes
place in the liver. The capability of hESCs to differentiate into
fairly mature hepatocytes (Agarwal et al., 2008; Basma et al.,
2009) may make them a suitable tool for testing the hepatic
metabolism of potential drugs. The third aspect is tissue toxicity,
which is based on the growing ability to obtain rather pure pop-
ulations of clinically relevant cells, such as cardiomyocytes and
neurons, from hESCs. Using these differentiated cells for cardio-
and neurotoxicity screens will allow tissue-specific assessment
of drug toxicity (Mandenius et al., 2011). During the past few
years, good progress has been made in all three fronts, and it
is predicted that in the future hESCs will be routinely used by
the pharmacological industry (Wobus and Loser, 2011).
Diseases in a Dish: Modeling Human Genetic Disorders
with ESCs
Mouse ESCs are the major tool for generating mouse models of
human diseases, and the contribution of transgenic mouse toCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 671
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in many disorders the mouse models fail to recapitulate the
human phenotypes. Therefore, hESCs represent an alternative
tool for modeling human diseases, by introducing mutations to
normal ESCs (Urbach et al., 2004) (Figure 2).
In the past 5 years, many different methodologies have been
used to manipulate the genome of hESCs, including homolo-
gous recombination by plasmids and BAC constructs (Song
et al., 2010) or by zinc finger and TALE nucleases (Hockemeyer
et al., 2009; Hockemeyer et al., 2011; Leavitt and Hamlett,
2011), and the use of RNAi to knock down specific genes (Tul-
pule et al., 2010). While both the efficiency and the specificity
of these methods have improved in recent years, off-target
activity remains a concern, as it may introduce ‘‘collateral
damage’’ that may jeopardize their applicability for disease
modeling. An alternative to induction of mutations in normal
hESCs is the isolation of genetically aberrant hESCs from blas-
tocysts carrying genetic diseases. Screening for diseased
embryos by the analysis of single blastomeres at the preimplan-
tation stage is becoming a more common methodology. Thus,
preimplantation genetic screening (PGS) is used to identify
chromosomal aberrations in human embryos, and hESCs can
be derived from such aneuploid embryos, generating in-vitro
models for chromosomal disorders such as Down syndrome
(Biancotti et al., 2010). In addition, preimplantation genetic
diagnosis (PGD) is conducted to screen for embryos that carry
monogenic disorders, and multiple ESC lines were derived
from such mutated blastocysts (reviewed in Ben-Yosef et al.,
2008).
Some of the derived disease model hESCs were analyzed
to identify disease characteristic phenotypes, either in the
undifferentiated state or after their differentiation in culture
(Colman and Dreesen, 2009). In developmental disorders,
these models also enabled the characterization of phenotypes
that are unique to the embryonic stage of the cells. Once
defining a phenotype of interest, these powerful models can
potentially serve to identify novel drugs that would enable
treatment of currently untreatable disorders. The abundance of
available cells could be exploited either for testing drugs
that target known candidate genes or for performing unbiased
high-throughput screens with libraries of varied molecular
entities.
It is clear that research on hESCs paved the way to the
analysis of human disorders using human iPSCs (Robinton and
Daley, 2012). It is also evident that the availability of somatic cells
from practically any human disorder has made the generation of
such models in human iPSCs very accessible for most labs.
There is some indication, however, that iPSC models may be
affected by an epigenetic memory from the somatic cells and
thus might be inferior to ESCs in reflecting developmental
aspects of the disease (Urbach et al., 2010). Nonetheless, iPSCs
are clearly becoming the system of choice for disease modeling,
andmost diseasemodels are already generated using this meth-
odology (Robinton and Daley, 2012).
The New Kids on the Block: Novel Types of ESCs
Traditionally, hESCs are derived from blastocysts of IVF em-
bryos and thus represent the outcome of the natural fertilization
process. Recently, however, new types of ESCs were intro-672 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.duced, diversifying the ESC toolbox with ESCs derived from
‘‘artificially generated’’ blastocysts (Figure 2).
Somatic cell nuclear transfer (SCNT) experiments, culminating
in the cloning of Dolly the sheep, paved the way for cloning other
mammals (Wilmut et al., 1997; Wakayama et al., 1998). In
humans, there were various attempts to generate nuclear trans-
fer (NT)-derived hESCs, but the initial successful report was
found to be fraudulent (Normile et al., 2006), leading the field
to stagnation. Successful SCNT with human cells was finally
reported last year, resulting in nuclear transfer (NT)-derived
hESCs (Noggle et al., 2011). Although these ESCs were triploid,
as the oocyte genome could not be removed, this study has
revitalized interest in using SCNT for deriving ‘‘personalized’’
ESCs. Comparing these NT-ESCs to normal ESCs and to iPSCs
would eventually be necessary to determine whether important
differences exist between these pluripotent cell types.
Another type of ESCs known for a long time in mouse
was finally generated in humans as well: human partheno-
genetic ESCs derived through parthenogenetic blastocysts
(Kim et al., 2007b). Such blastocysts are generated by the
activation of unfertilized oocytes, which undergo duplication of
their genomic content and thus harbor two copies of the
maternal genome. Human parthenogenetic pluripotent stem
cells may serve for the generation of MHC-matched cells for
transplantation, as was demonstrated in mouse (Kim et al.,
2007a), and may also be used for the study of imprinting (Stelzer
et al., 2011).
A third striking type of ESCs was recently reported in mouse.
Using the same technique of activating haploid oocytes,
mESCs were derived from parthenogenetic embryos grown
under specific culture conditions, and were than FACS-sorted
for low DNA content, resulting in haploid mESC lines (Elling
et al., 2011; Leeb and Wutz, 2011). These haploid mESCs may
become an invaluable tool for forward and reverse genetics,
as was elegantly demonstrated in these two groundbreaking
papers. Similar attempts to generate haploid hESCs are cur-
rently underway, hopefully to be crowned with success.
The Pluripurpose Cell: Using ESCs beyond Pluripotency
Research
One of the most interesting developments in the ESC field in
recent years is the way it has been integrated into affiliated
research fields and influenced all areas of genetics, epigenetics,
and cell biology. Indeed, the boundaries between ESC research
and other research fields often become blurry, as studies ‘‘with’’
ESCs, rather than ‘‘of’’ ESCs, are already rapidly accumulating
into a significant body of work.
ESCs have been used as a tool for the investigation of basic
questions in various areas of biology, and by now these cells
are responsible for major advancements ‘‘outside’’ the tradi-
tional borders of ESC research. To name just a few examples,
the identification of an active DNA demethylation enzyme
(Bhutani et al., 2010), lincRNAs (Guttman et al., 2009), and exten-
sive transcription initiation (Guenther et al., 2007), as well as
improvements in genomic techniques such as zinc finger nucle-
ases (Collin and Lako, 2011) and high-resolution methylation
mapping (Jeddeloh et al., 2008), are all discoveries made in
ESCs but with implications that go far beyond the biology or
the manipulation of pluripotent cells.
Cell Stem Cell
PerspectiveIt seems, therefore, that ESCshave recentlymadegreat impact
on a variety of research arenas, serving as a sort of ‘‘pluripurpose
cells,’’ awell characterized in vitro systemof normal humanprolif-
erating cells that might possibly even replace HeLa cells as
‘‘default’’ cells of choice. ESCs have thus gone beyond what is
usually perceived as ‘‘ESC research’’ and are extensively used
in the biological and biomedical sciences (a fact that is unfortu-
nately overlooked in some public discussions, when the neces-
sity and utility of these cells is drawn into question).
Concluding Remarks: The Next 5 Years
Soon after Yamanaka and Thomson first reported the generation
of human iPSCs, President George W. Bush referred to this
achievement as a ‘‘scientific advancement within ethical bound-
aries’’ (Kolata, 2007); however, the expectation that iPSCswould
replace embryonic stem cells (ESCs) in the study of pluripotency
has proven wrong. On the contrary, the vibrant and flourishing
ESC research community received a substantial boost from
the induced pluripotency breakthrough, and since 2006 these
two pluripotent cell types have complemented and promoted
each other (Scott et al., 2011).
The rapid discovery rate in the ESC field, with the surprising
twists and turns it sometimes takes, makes it very difficult to
predict where ESC research will be 5 years from now. Nonethe-
less, the achievements of recent years do seem to suggest
that ESC research is far from reaching its full capacity and is
predicted to continue expanding. Geographically speaking, the
gap that still exists betweenmESCs and hESCs in terms of coun-
tries involved suggests that more countries are probably about
to get actively engaged in hESC research. From a basic research
point of view, there is no doubt that much is left to be discovered
regarding the pluripotent state and its control, with an emphasis
on combining the complex multilayered regulation into a
coherent regulation circuitry. From the perspective of regenera-
tive medicine, data regarding the safety and efficacy of current
and future clinical trials will undoubtedly determine when ESC
research is mature enough to fulfill its promise in the clinic, and
success in this arena is bound to draw more private companies
into the field. Novel ESC types and reprogramming methods,
possible advancements in the generation of human-animal
chimeras, and increasing numbers of disease models are further
reasons to believe that exciting years lie before us.
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